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Abstract
Sitagliptin (STG), a drug for treating Type Ii Diabetes Mellitus (T2DM), has been associated with severe joint pain
in some patients. In this paper the metabolic profile of the drug has been investigated in order to determine
metabolism and formation of reactive compounds which may contribute to this adverse effect. Metabolism of STG
was investigated in vitro by incubation with freshly isolated Sprague-Dawley rat hepatocytes, to characterize Phase I
and II metabolites, and the reaction mixture analysed on a zwitter ionic hydrophilic interaction (ZIC®-HILIC) column
using LC-MS and LC-MS2 utilising electrospray ionization (ESI) in the positive ion mode.
STG was metabolised to yield eleven metabolites, but in total only 3.1% of the parent drug was metabolised over
2 hrs incubation. These metabolites were structurally characterized on the basis of accurate mass analyses and the
major metabolic routes for STG determined to be via aromatic oxidation (0.86%) and desaturation of N-C and C-C of
the piperazine (0.44%).
Novel metabolites of STG detected using these methods included STG N-glucuronide (M6) and a di-ketone
metabolite (M4), hydroxylation of both the amine group and aromatic ring followed by formation of glucuronide
metabolites (M5, M5’), oxidative desaturation of NH2 and di-hydroxylation of metabolites followed by loss of HF.
Also, observed was an N-sulfate metabolite (0.07%) and acetylation followed by glucuronide conjugation was
also found in trace amounts (<0.01%). MS2 fragment ions provide additional structural confirmation providing a
possible structure for most metabolites such as by fragment ion loss of the glucuronide group (176 Da) from
metabolite M5 and loss of the phenolic sulfate (80 Da) of N-Sulfate metabolite (M7).
Reduction reaction of piperazine ring probably generates highly electrophilic metabolite of STG, which may be
susceptible to produce adverse effects. Furthermore, N-oxidation reaction forming reactive intermediates metabolic
to give a hydroxylamine metabolite that may undergo further reactions to yield electrophilic intermediate metabolites.
Keywords: STG; DPP-4: Dipeptidyl peptidase 4; Metabolism; ZIC-
HILIC; Mass spectrometry
Abbreviations:
STG: Sitagliptin; LC/MS: Liquid Chromatography/Mass
Spectrometry; LC–MS2: Liquid Chromatography–Multiple Mass
Spectrometry; ESI: Electrospray Ionization; CID: Collision-Induced
Dissociation; T2DM: Type 2 Diabetes
Introduction
Diabetes mellitus is a disorder of metabolism, which is a major
public health problem in all parts of the world, and recently the World
Health Organization suggested that in all parts of the world almost 3
million deaths annually can be attributed to diabetes. Within 10 years,
it is expected that about 333 million people world-wide will suffer from
diabetes mellitus; with Type 2 Diabetes Mellitus (T2DM) representing
about 90-95% of cases diagnosed [1].
STG is an antidiabetic agent of the Dipeptidyl Peptidase-Iv Inhibitor
(DPP-IV) class [2]. It was approved by the Food and Drug
Administration (FDA) in October 2006 and produced as a single
therapy to treat T2DM by Merck Pharmaceutical Company under the
trade name Januvia®. These DPP-IV inhibitors are used as
monotherapy, and as add-on therapy in patients with T2DM. The FDA
agreed to the sitagliptin/metformin (JanumetTM, Merck & Co.)
combination in April 2007 as an assistive treatment in combination
with diet and exercise to improve control of blood sugar in adult
patients suffering from T2DM [3-5].
Recently, the FDA warned that some T2DM medicines such as STG
caused severe joint pain; these symptoms were relieved after the
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patient discontinued the drugs. At present the mechanism responsible
for this adverse effect is not known, either in terms of the chemical
species involved or the physiological process affected. Understanding
the metabolic pathways and formation of reactive metabolites will aid
understanding of in the vivo metabolism, likely pharmacokinetics and
adverse effects of this class of medicine [6]. The chemical structure of
STG is shown on Figure 1.
Figure 1: Chemical structure of SGT.
In the literature, there are Gas Chromatography-Mass Spectrometry
(GC-MS) methods for the determination of STG in biological samples.
However, these chromatographic studies require a complicated process
to enable identification of trace amounts of STG metabolites using
drying and then derivatisation by N-
methyltrimethylsilyltrifluoroacetamide prior to GC-MS analysis and
conversion into its N-TMS amine derivative, and these processes might
affect the stability of some metabolites which are formed in trace
amounts or indeed they may simply not be volatile enough for GC-MS
analysis [7]. On the other hand, Vincent et al. recently reported the
phase I and II metabolism of [14C] STG and six metabolites at trace
levels in human plasma, urine and faeces using LC-MS2 and
radiometric detection using the TurboIonSpray interface operated in
the positive ion mode. Six phase I and II metabolites of STG were
observed in both human urine and faeces and these were shown to be
products of hydroxylated, N-sulfated STG and two metabolites formed
by oxidative desaturation of the piperazine ring followed by
cyclization. It was observed that, in all human subjects, the
glucuronides were further transformed and were not detected in faeces
samples [8].
Similar observations were shown in rats and dogs, where, as in
humans, approximately 10-16% of the radiolabeled oral dose was
recovered in the rat and dog excreta as phase I and II metabolites. All
the metabolites observed in human plasma, urine, and faeces were also
observed in rat and dog plasma, urine, bile, and faeces, as well as in
incubations in vitro with rat, dog, and human liver microsomes.
However, metabolism was minimal in all species in vitro and in vivo.
Results from in vitro experiments with recombinant P450s and
monoclonal anti-P450 antibodies showed that the oxidative metabolite
of STG in human liver microsomes is catalysed primarily by CYP3A4
with some minor contribution from CYP2C8 [9]. The authors did not
detect any other products arising from Phase II metabolism except the
glucuronide and sulfate metabolites.
As knowledge of the ADME processes for reactive metabolites is a
prerequisite for their toxicological risk assessment it is prudent to
elucidate both the phase I and II metabolic pathways for STG
especially in the long term administration for this kind of medication.
This paper seeks to address this deficiency by presenting the
elucidation and profile of both phase I and phase II metabolic events in
rat hepatocyte preparations using LC-MS and LC-MS2 methods.
Experimental
Chemical and reagents
All reagents were of commercial quality (obtained from Sigma–
Aldrich, Gillingham, UK, Alfa-Aesar, Heysham, UK or Fisher
Scientific, Loughborough, UK) and used without further purification.
Sitagliptin phosphate (STG) was obtained from Kemprotec Limited,
UK. HPLC grade acetonitrile was obtained from Fisher Scientific, UK,
and formic acid (98%) was obtained from BDH (DOREST, UK).
The LC separation was performed using a Exactive Orbitrap
(Thermo Fisher Scientific, Hemel Hempstead, UK), which was
operated in the positive mode, A ZIC-HILIC Column 5 um 150 mm ×
4.6 mm (HiChrom, Reading, UK), and acquisition was performed
using XCalibur software. Fragmentation experiments were carried out
using LTQ Orbitrap (Thermo Fisher Scientific, Hemel Hempstead,
UK).
Data processing
LC/MS raw files were processed by Thermo Sieve software which
can provide variances in the plots, which were highlighted, and the
exact masses of ions yielding the difference could be detected. The
parameters used in this software were: time range 4-30 min, mass
range 75-800 amu, frame width 0.02 amu and Rt width 2.5 min [10]. It
can be shown clearly that this software detected a difference in the
intensity peaks of the metabolite ions between STG incubated with
hepatocytes for 120 min and STG, incubated with buffer alone, and
hepatocytes incubated in the absence of STG after 120 min.
Biotransformation of STG in Sprague-Dawley rat
hepatocytes
All animal procedures adhered to UK Home Office Guidelines and
were carried out under Licence PPL/60/3685. The hepatocytes were
prepared from male Sprague-Dawley rats (body weight range: 200–250
g, bred in the University of Strathclyde) by collagenase perfusion of the
livers using a modification of the method by Moldeus et al. [11,12].
The cell viability was confirmed using a Trypan blue exclusion test, and
was >80%. STG (100 μM, a standard concentration used to screen
metabolic pathways) was incubated in 50 mL round-bottomed flasks
with hepatocytes (2 × 106 viable cells mL-1) in Krebs-Henseleit (K-H)
buffer containing 12.5 mM HEPES (pH 7.4). The samples were
incubated with constant rotation at 37°C under an atmosphere of
oxygen: carbon dioxide (95:5) for 120 min. Control incubations of (i)
rat hepatocytes (in the absence of STG) and (ii) solutions of (STG)
dissolved in K-H buffer (pH7.4) was also carried out. All incubations
were carried out in triplicate, using three independent animals.
Sample preparation
Aliquots (0.5 mL) were removed at 0 min, 30 min, and 120 min
from the incubations, and quenched by addition of acetonitrile (1 mL).
The samples were centrifuged (104 rpm, 15 min) and any remaining
protein removed by further addition of acetonitrile (0.2 mL) and
subsequent filtration through a Biotage Isolute® PPT+protein
precipitation plate (Biotage Limited, Sweden). These crash plates are
attached to a vacuum manifold, and each sample mixed with 0.5 mL of
acetonitrile to allow the protein to precipitate, then the filtrate was
collected and analysed by either LC-MS or LC-MS2.
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The efficiency of recovery from hepatocyte matrix was determined
to be 102.6% ± 20.7% (for STG, n=3, ±SD)
Liquid chromatography-mass spectrometry (LC-MS)
Liquid chromatography-mass spectrometry (LC-MS) data were
acquired using an Orbitrap Exactive instrument (Thermo-Fisher
Corporation, Hemel Hempstead, UK). Sample analysis was carried out
with positive ion ESI detection. The mass scanning range was 75-1200
m/z, while the capillary temperature was 250°C, spray voltage was +4.5
kV and the sheath and auxiliary gas (nitrogen) flow rates were 45 and
15, respectively (units not specified by the manufacturer). The LC-MS
system (controlled by Xcalibur Ver. 2.0, Thermo-Fisher Corporation,
Hemel Hempstead, UK) was run in binary gradient mode with an
injection volume of 10 µL. Solvent A was aqueous formic acid (0.1%
v/v) and solvent B was formic acid (0.1% v/v) in acetonitrile; the flow
rate was 0.3 mL min−1. A ZIC®-HILIC (150 mm × 4.6 mm i.d., particle
size: 5 µm) column fitted with a ZIC®-HILIC guard column (HiChrom
Limited, Reading, UK) was used for all analyses. The gradient
programme was as follows: 20% A (0 min) to 50% A (at 12 min), to
50% A (at 26 min), to 80% A (at 28 min), to 80% A (at 36 min), to 20%
A (at 37 min) and finally re-equilibration with 20% A to 45 min. LC-
MS2 spectra were obtained by using an LTQ Orbitrap (Thermo-Fisher
Corporation, Hemel Hempstead, UK) with the same source, control
software and chromatographic conditions specified above. The selected
precursor ions were fragmented with a CID voltage of 40 eV. Data
processing was carried out using SIEVE Ver. 1.2.1 (ThermoFisher,
Hemel Hempstead UK), ToxID Ver. 1.2.1 (ThermoFisher, Hemel
Hempstead UK) and MetWorks Ver. 1.3 (ThermoFisher, Hemel
Hempstead UK) software.
Results and Discussion
Confirmation of Sprague-Dawley rat hepatocyte viability
The viability of the freshly isolated hepatocytes was 79.5 ± 4.6%, and
exposure to STG had no significant effect on viability compared with
cells incubated in K-H buffer alone for up to 2 hrs.
Biotransformation of STG in Sprague-Dawley rat
hepatocytes
Using the high resolution mass spectrometer, 11 potential STG
metabolites were detected by using SIEVE software to compare the
control incubation with the hepatocyte incubation containing STG.
Only 3.1% ± 0.12% of the parent STG was metabolised by the end of
the two hr incubation. Five of the eleven metabolites have been
previously identified [8], along with products arising from sulfation,
glucuronidation, acetylation, hydroxylation and other pathways [9].
Thus it was found that rat hepatocytes catalysed both phase I and
phase II metabolism of STG and overall eleven metabolites were
putatively identified (Table 1).
Metabolite Rt (min) m/z Formula (ppm) MS2 Base Peak Other Ions
STG 9.6 408.13 C16H16F6N5O (0.224)  235  193(26),391(9),174(4)
M1 8.25 424.12 C16H16F6N5O2 (-0.001)  391  193(12),235(2)
M1' 9.7,10.1 424.12 C16H16F6N5O2 (-0.001)  406  235(6),191(5),193(3)
M2 9.72 406.11 C16H14F6N5O(-0.3134)  191  174(6),233(4)
M2’ 5.67 406.11 C16H14F6N5O(0.206)  191  174(6)
M3 5.67 422.10 C16H14F6N5O2 (0.781)  193  404(96),389(63), 285(49),191(44),207(10)
M4 5.6 407.09 C16H13F6N4O2 (0.026)  193  191(16),192(11),389(1)
M5 6.4 600.15 C22H24F6N5O8 (-0.230)  424(-gluc)  582(55),391(26),191(10),193(10),
408(8)
M5'- 9.95,11.1 600.15 C22H24F6N5O8 (-0.430)  406  582 (5)(-H2O),424(3)
M6 9.34 584.16 C22H24F6N5O7 (0.353)  530
(-3H2O)
 486(53),408(7,-gluc)
M7 5.12 488.08 C16H16F6N5O4S (-0.11)  408(-SO3)  470(3)(-H2O)
M8 6.26 452.12 C17H16F6N5O3 (-0.025)  ND  
M9 6.3 628.15 C23H24F6N5O9(-0.383)  516  408(30),452(28,-gluc),404(20),
610(19,-H2O)
M10 5.8 440.12 C16H16F6N5O3 (0.147)  422(-H2O)  
M11 10.7 422.12 C16H17F5N5O3 (-0.187)  404(H2O)  
Table 1: Phase I and phase II metabolism of STG.
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The elemental composition and retention times of the metabolites
are listed in Table 1. The mass error (when compared to their
theoretical masses) of all the detected metabolites were within ±0.5-1
ppm of their assigned elemental composition (Table 1), however, the
most abundant metabolites after 30 mins incubation were proposed to
be aromatic hydroxylation metabolites (M1’, tR=9.7 min/10.1 min; m/
z=424.12), and desaturated metabolites formed through desaturation
of N-C and C-C of the piperazine ring (M2 and M2’ respectively,
tR=9.7 min, 5.7 min; m/z=406.11). M2 was formed from STG by
conversion of a tertiary amide to a quaternary amide via C-N
desaturation. The mass spectral fragmentation pattern (Figure 2)
shown included fragment ion (m/z 191), and Liu showed similar
findings and obtained the same fragmentation pattern. Thus M2 was
formed through desaturation of C-N and M2’ through desaturation C-
C of piperazine ring [13].
Figure 2: The mass spectral fragmentation pattern.
The levels of most of these metabolites increased further between 30
and 120 min of incubation with a corresponding slight decrease in the
level of unmetabolised drug (STG, tR=9.6 min).
In contrast, the level of (M8, tR=6.3 min; m/z=452.12) was similar
between 30 min and 120 min and there was an increase in the levels of
its corresponding glucuronide (M9, tR=6.5 min; m/z=628.15). The
sulfate metabolite (M7, tR=5.12 min; m/z=488.08) could also be clearly
observed after 120 min of incubation and it is considered a stable non-
toxic conjugate. In some cases chromatographic information can be
used to differentiate isomeric possibilities. Thus metabolite (M1) is
proposed to result from hydroxylation on the amine group at the
nucleophilic nitrogen forming a hydroxylamine rather than
hydroxylation of the aromatic moiety of STG (M1’), M1 and M1’ elute
at a different retention time (tR=8.25 min, tR=9.7; 10.1 min
respectively) on the ZIC®-HILIC column.
The biotransformation of (STG) observed following its incubation
with Sprague-Dawley rat hepatocytes is summarised. The dynamic
range of the instrument was sufficient to show both major and minor
metabolites. Metabolite M1 and M1’, eluted at 8.25 and 9.7 min, and
had a protonated molecular ion [M+H]+ at m/z 424.12 which indicates
possible hydroxylation at NH2 (M1) as the largest fragment ion was
observed at m/z 391, which can be attributed to the loss of (NH3-OH)
or loss of 18 D at the aromatic position metabolite (M1’) to produce
fragment ion m/z 406.
Moreover, metabolite M2 and M2’, showed the same protonated
molecular ion [M+H]+ at m/z 406.1; the molecular ions were 2 Da less
than that of STG parent ion, indicating loss of 2 Hydrogen atoms. Due
to the lack of reference standards in this study the results could not
define the exact desaturation positions of M2 and M2’. However, the
advantage of the high resolution of mass spectrometry in assignment
of the largest fragment at m/z 191 showed the two possible structures
of these metabolites as desaturated in C-C and C-N of the piperazine
ring (Figure 2). In addition, the results of this study indicate that STG
is metabolised to an electrophilic form (M2) which is an ionized
metabolite, and it may be implicated in adverse effects of STG, as it is
an electrophilic entity capable of irreversible reaction with tissue
nucleophiles [14].
When the primary amine underwent N-oxidation it formed a
hydroxylamine. This provides a pathway for metabolic deamination.
Thus STG is transformed to a hydroxylamine that then underwent
dehydration to an imine. This is subjected to further metabolic
oxidation to give an oxime because the imine had hydrogen attached to
the nitrogen (M3, m/z 422.10). The carbon of the oxime is electrophilic
and water attacks it to form a carbinolhydroxylamine that is then
hydrolyzed to form a ketone and hydroxylamine. Thus M4 has a
protonated molecular ion [M+H]+ at m/z 407.09 and was identified as
a deamination metabolite of STG (Scheme 1) [15].
Several enzyme systems such as CYP dependent FMOs can catalyze
N-Oxidation reactions [16,17] and this pathway has the potential to
lead to metabolites that can damage cells via multiple pathways.
Metabolites, such as the N-hydroxyl metabolites, can redox cycle to
produce reactive oxygen species and other free radicals, which can
damage membranes and lead to oxidative stress [18,19].
The primary amine group in STG reacted to form N- glucuronide
metabolites (M6, tR=9.3 min; m/z=584.15). The fragmentation pattern
showed a mass shift of 176 Da compared with the parent STG, because
the amine nucleophilic functional groups react at the acetal carbon of
the sugar, inverting the configuration at that site to give an N-
glucuronide conjugate. This reaction is catalyzed by UDP-glucuronyl
transferase. The hydroxylamine group in M1 also can react to form O-
glucuronide metabolites (M5, M5’, tR=6.4, 10 and 11 min; m/
z=600.11). Glucuronide formation is an important step in the
elimination of many important exogenous substances from the body;
the major glucuronide metabolites observed in the current work were
M5 and M6. There was also a glucuronide as a minor metabolite, an N-
carbamoyl glucuronidation (M9, tR=6.5 min; m/z=628.15).
Karabulut et al. reported that the number of apoptotic cells was the
same in the pancreas of healthy and type-2 diabetic rats after STG
administration. Serum glutathione levels did not change in either
group. Glutathione conjugated metabolites were not detected in our
study [20], however, the N-oxide metabolite needs further study to
fully characterise its pharmacological/toxicological effects.
Defluorination of STG occurred forming (M11, tR=10.4 min; m/
z=422.12) in trace amounts after two hrs of incubation, presumably
after nitrogen and aromatic hydroxylation (M10, tR=9.8 min; m/
z=440.12).
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Scheme 1: Deamination metabolite of STG.
Metabolic profiling of Sitagliptin (STG)
Drugs are eliminated from the body by excretion and by
transformation to metabolites. These processes occur simultaneously,
but which of these processes predominate varies from one drug to
another. As the amount of drug in a system depends on both its rates
of absorption and elimination and the amount of a specific metabolite
present also depends on its rate of formation and elimination. The
metabolic profiles of STG (pKa=8.78; Log P=1.26) were determined
using three separate incubations of the drugs with isolated rat
hepatocytes (Figure 3).
The relative levels of the detected metabolites of STG indicate that
eleven metabolites were identified in the freshly isolated cells. The
product-ion spectrum of protonation recorded at 40 eV collision
energy is shown in Figure 3 and only aromatic hydroxylation STG
(M1’, m/z=424.12) was formed in large amounts. In addition, the
formation of metabolite (M5’, m/z=600.15) increased after two hrs
incubation period by approximately 100%. In the case of (STG) the
histogram indicates that the major metabolites of STG were: (M1’, m/
z=424.11), (M2, m/z=406.10), (M4, m/z=407.09) and (M5’, m/
z=600.15) (Figure 3). The amount of (M3) and (M6) increased slowly
throughout the two hr incubation period. The majority of Phase II
metabolites identified in (STG) were found at low levels at 30 min and
increased slightly by 120 min. The N-sulfate metabolite (M7, m/
z=488.08 ) increased slowly though the level was low at 30 as well as
120 min, moreover (M8, m/z=452.12), (M9 m/z=628.15) and (M11 m/
z=422.12) were identified at only trace amounts, however, the
sensitivity and high resolution of the instrument was sufficient to show
these minor metabolites.
In a similar case in a healthy male, Herman showed that almost all
STG was excreted unchanged in urine and faeces after oral
administration. It was eliminated 87% in urine and 13% in the faeces.
Renal clearance involving active tubular secretion was the main
elimination pathway [21]. In our study, as can be seen from Table 1,
the results obtained from the preliminary analysis of rat hepatocyte
incubations showed both phase I and phase II metabolism of STG.
However, the metabolism of STG in liver cells was also minimal. M+H
was the major metabolite formed. A considerable amount of literature
has been published on STG metabolism. All the metabolites reported
in previous studies have been produced in our study when hepatocytes
were incubated with STG, except for the glutathione conjugate
reported by Beconi [9] which was absent in our study.
The most obvious finding to emerge from the analysis is that total
metabolism of STG was only about 3%. It can thus be suggested that
the adverse effects that were reported recently may be caused by the
parent drug. This view is supported by Swallow who reported that high
metabolic stability and bioavailability of STG of 87% were
demonstrated in vivo in healthy volunteers and the author showed that
renal clearance of unchanged STG accounted for approximately 70% of
the total plasma clearance of STG. Therefore, further studies of the
adverse effects of STG which take these variables into account, will
need to be undertaken [22,23].
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Figure 3: The metabolic profiles of STG (pKa=8.78; Log P=1.26) were determined using three separate incubations of the drugs with isolated
rat hepatocytes.
Conclusion
The data presented both confirm and expand upon previously
reported observations through the identification of all Phase II
metabolites, however, no evidence of the formation of ring cyclization
after oxidative desaturation of the piperazine were detected in the
current study. STG shows some novel metabolite pathways such as a
deaminated metabolite in which the amino group is replaced by
oxygen. The key pharmacokinetic parameters for STG reported herein
may be of significance to medical pharmacologists and can be used to
predict both the in vivo metabolism and the likely pharmacokinetic
effects of STG within this class of anti-diabetic substances [24].
The present study confirms previous findings of STG metabolism.
This study did not confirm formation of a glutathione conjugate
metabolite, and for those new metabolites such as diketone metabolite
of STG, N-hydroxylation and oxime metabolites, further studies are
needed to investigate the pharmacological evaluation.
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